Avantor and the National Institute of Bioprocessing Research and Training (NIBRT) are teaming up to address downstream bottlenecks in buffer preparation when producing monoclonal antibodies (mAbs). As part of the joint effort, Avantor is providing in-line dilution systems for hands-on experience at NIBRT's training and research facility dedicated to supporting the global bioprocessing industry.
US Avantor's technology adds to Ireland-based NIBRT's full complement of bioprocessing capabilities.
Dr Ger Brophy, Executive VP of Biopharma Production for Avantor, said: "Demand for therapeutic biologics is increasing and this will require increased manufacturing productivity. At the same time, there is significant pressure on the biopharma industry to reduce overall costs while ensuring that safety and quality are not compromised. This has resulted in initiatives to improve efficiency and increase flexibility in bioprocessing facilities. Buffer management is a key process step which is prime for optimisation."
Buffers are a critical component when producing and purifying mAbs and are extensively used in upstream and downstream production. Recent activities in upstream optimisation have resulted in increasing production yields, which has now placed pressure on downstream purification resources. In addition, demand for multi-product facilities has placed a strain on the capacity for traditional buffer preparation.
Buffer management can help advance bioprocessing production by reducing downstream bottlenecks and costs. Avantor's collaboration with NIBRT will provide buffer management training to help mitigate downstream challenges, which will help new therapies to reach patients faster and more cost-effectively.
Dominic Carolan, NIBRT CEO, said: "This collaboration further advances our mission of providing a world-class research and training centre of excellence. Technicians and professionals will benefit from access to the latest bioprocessing production knowledge, technology and innovation in buffer management. We are delighted to be working closely with Avantor to support the biopharmaceutical industry."